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mammary tumors. Again, the necessity 
of such accessory proteins in tumor pro-
gression offers novel avenues for thera-
peutic intervention.
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E2-EPF ubiquitin carrier protein (UCP) is a member of an E2 family of enzymes that catalyzes the ligation of ubiquitin to proteins 
targeted for destruction by the proteasome. UCP is overexpressed in common human cancers, suggesting its involvement in 
oncogenesis, but a physiologic target of UCP has not been identified. In a recent report published in Nature Medicine, Jung et 
al. identified von Hippel-Lindau (VHL) tumor suppressor protein, which targets the α subunit of hypoxia-inducible factor (HIF) 
for ubiquitin-mediated destruction, as a bona fide substrate of UCP and demonstrated a potential pVHL-HIF pathway-dependent 
role for UCP in cancer development.95cancer cell august 2006 
von Hippel-Lindau disease (OMIM 193300) 
is a rare hereditary cancer syndrome that 
is characterized by the development of 
hypervascular tumors in multiple, and yet 
specific, organs, including the cerebellum, 
retina, adrenal gland, and kidney. VHL 
disease is caused by the inheritance of 
a faulty VHL gene, and the tumors arise 
when the remaining wild-type VHL allele 
is lost or inactivated via mutation, deletion, 
or promoter methylation in a susceptible 
cell. Biallelic inactivation of VHL has also 
been associated with the development of 
sporadic clear cell renal cell carcinoma 
(CC-RCC), the most common form of 
kidney cancer (Kaelin, 2002).
pVHL is a substrate-recruiting compo-
nent of an E3 ubiquitin ligase called ECV 
(Elongins/Cul2/pVHL) that is structurally 
and functionally analogous to the SCF 
(Skp1/Cdc53/F box protein) complex. 
Crystal structure of the pVHL/elongin B/
elongin C complex revealed two functional 
domains on pVHL: α and β (Stebbins et 
al., 1999). The α domain binds elongin C, 
which acts as a bridge connecting pVHL to 
the scaffold component Cul2, which binds 
Rbx1 and a cognate E2 ubiquitin-conju-
gating enzyme, Cdc34 or UbcH5. The β 
domain acts as a substrate-docking site. 
The majority of tumor-associated VHL 
mutations map to the surface residues 
on either domain, suggesting that these domains are functionally important for the 
tumor suppressor activity of pVHL.
To date, several cellular proteins have 
been identified as pVHL binding proteins 
that are subjected to ECV-dependent 
ubiquitylation. However, the most con-
vincing substrate that continues to shed 
significant insight into the tumor sup-
pressor function of pVHL is HIFα (see 
Figure 1). HIF is a major heterodimeric 
transcription factor consisting of α and β 
subunits that transactivates 60 or more 
hypoxia-inducible genes, including vas-
cular endothelial growth factor (VEGF; 
also known as vascular permeability fac-
tor), erythropoietin (EPO), and glucose 
transporter-1 (GLUT1) to promote angio-
genesis, oxygen-carrying erythrocyte 
production, and anaerobic metabolism, 
respectively, in adaptation to compro-
mised oxygen availability. While the HIFβ 
subunit (also known as aryl-hydrocarbon 
receptor nuclear translocator [ARNT]) is 
abundantly expressed irrespective of oxy-
gen tension, the HIFα subunit is oxygen 
labile. In the presence of oxygen, HIFα is 
hydroxylated on conserved prolines within 
the oxygen-dependent degradation (ODD) 
domain by prolyl hydroxylase domain-con-
taining enzymes (PHDs). Prolyl hydroxyl-
ation is both necessary and sufficient for 
the binding of HIFα by pVHL and subse-
quent ubiquitylation via ECV. Accordingly, hypoxia or mutation in pVHL leads to the 
stabilization of HIFα. HIFα then dimerizes 
with HIFβ to form an active transcriptional 
complex, which engages the 5′-RCGTG-
3′ hypoxia-responsive elements (HREs) 
within the promoter/enhancer of hypoxia-
Figure 1. the uCP-pVHL-HIF pathway in cancer
see text for details. eBC, elongins B and C; N8, 
NEDD8; ub, ubiquitin; OH, hydroxyl group.
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adaptive responses to hypoxia (Kaelin, 
2002).
Tumor growth is inevitably challenged 
by the limited diffusional capacity of oxygen 
from the nearest blood vessel, generating 
a progressively more hypoxic tumor interi-
or. Thus, the induction of HIFα observed in 
most solid tumors is in part a result of the 
general oxygen-sensing pathway. In addi-
tion, cancer-causing mutations in certain 
tumor suppressor genes have been iden-
tified to bypass the necessity of low-oxy-
gen tension to initiate a “pseudo” hypoxic 
response to promote tumor development 
(Ohh, 2006). For example, mutations in 
TSC2 tumor suppressor gene increase 
the level of HIF-1α via the mammalian 
target of rapamycin (mTOR)-dependent 
and -independent mechanisms that may 
involve chromatin remodeling. The loss of 
PTEN is correlated with increased HIF-
1α levels, presumably via the Akt/protein 
kinase B signaling pathway. Mutations in 
succinate dehydrogenase (SDH) result in 
the cytosolic accumulation of succinate, 
which inhibits PHDs, leading to the sta-
bilization and activation of HIF-1α. The 
loss of p53 is associated with enhanced 
HIF-1α expression, presumably due to 
the attenuation of Mdm2-mediated ubiq-
uitylation of HIF-1α upon the absence of 
p53. Perhaps the most striking and direct 
mechanism of stabilizing HIFα involves 
mutations in pVHL, which permit HIFα to 
escape from ECV-dependent ubiquitin-
mediated degradation.
In a recent article published in Nature 
Medicine, Jung et al. report that E2-EPF 
UCP, a gene associated with liver and 
gastric cancers that is capable of increas-
ing the expression of the HRE-driven lucif-
erase reporter gene, forms a complex with 
pVHL and catalyzes an E3-independent 
ubiquitylation of pVHL, promoting the 
destruction of pVHL via the 26S pro-
teasome (Jung et al., 2006) (see Figure 
1). Under a normal physiologic state, 
the expression of UCP and HIF-1α was 
undetectable in the mouse liver, but upon 
transduction with an adenovirus-encoded 
UCP, the level of pVHL decreased with 
the concomitant accumulation of HIF-
1α. In numerous transformed cell lines, 
as well as primary and metastatic liver, 
colon, and breast tumors, an inverse 
relationship between UCP and pVHL 
was observed where a detectable UCP 
expression correlated with decreased 
pVHL and increased HIF-1α expressions. 
In addition, UCP depletion attenuated the 
96 growth rate and invasiveness of tumor 
cells, while UCP overexpression promot-
ed tumor progression and lung metastasis 
of melanoma cells in a mouse xenograft 
model. Previously, Kondo et al. showed in 
a mouse xenograft model that the tumori-
genic potential of 786-O (VHL−/−;HIF-1α−/−) 
CC-RCC cells is critically dependent on 
the expression of HIF-2α (Kondo et al., 
2002). Importantly, Jung et al. demon-
strate that, in 786-O cells lacking pVHL, 
overexpression or depletion of UCP nei-
ther had an effect on HIF-2α expression 
nor influenced the tumor growth rate of 
implanted 786-O cells in mice, suggesting 
that the effect of UCP on tumor growth is 
mediated by the pVHL-HIF pathway (Jung 
et al., 2006).
Although it is not known how UCP 
is upregulated in transformed cells, its 
oncogenic expression is predicted to 
result in the induction of HIFα via pVHL 
degradation in virtually any tissue type, 
since VHL is ubiquitously expressed. 
Curiously, however, germline inheritance 
of a mutated VHL allele causes tumor 
development in few select organs. This 
would suggest that a loss or functional 
inactivation of the remaining wild-type 
pVHL in certain tissues is insufficient for 
cellular transformation, assuming that the 
second “hit” is equally probable in all cell 
types throughout the body. Furthermore, 
there is compelling evidence to suggest 
that the functional loss of pVHL even in 
VHL disease-associated tumors is inad-
equate for malignant transformation. For 
example, a conditional inactivation of VHL 
in the renal proximal tubules resulted in 
glomerular and tubular renal cysts without 
the presentation of tumors (Rankin et al., 
2006), recapitulating the human condition 
where the loss of VHL has been observed 
in preneoplastic cysts (Lubensky et al., 
1996), and suggests that other genetic 
events are required for the progression 
of the premalignant cysts to CC-RCC. A 
certain mutation in pVHL is also associ-
ated with congenital polycythemia (Ang 
et al., 2002). However, these individu-
als are not at a higher risk of developing 
cancer, despite enhanced HIF activity as 
evidenced by the increased levels of EPO, 
VEGF, and GLUT1. Thus, UCP-mediated 
depletion of pVHL in non-VHL disease-
associated or VHL disease-associated tis-
sues will likely require additional genetic 
mutations/alterations for tumorigenesis.
Moreover, pVHL has other binding 
partners, some of which are subjected to 
ECV-dependent degradation while others are not subjected to the ubiquitin pathway 
(Ohh, 2006). For example, atypical pro-
tein kinase C, VHL-interacting deubiqui-
tinating enzyme (VDU), and the seventh 
(Rpb7) and the large (Rbp1) subunits of 
RNA polymerase II are ubiquitylated via 
ECV. SP1 transcription factor, VHL-asso-
ciated KRAB-A domain-containing protein 
(VHLaK) transcription repressor, micro-
tubules, and fibronectin bind to pVHL 
without being targeted for the ubiquitin-
mediated destruction. In addition, pVHL 
was unexpectedly shown to directly bind 
and stabilize p53 by suppressing Mdm2-
mediated ubiquitylation, and to induce the 
acetylation of p53 upon genotoxic stress 
by promoting p53-p300 interaction, result-
ing in increased p53 transcriptional activ-
ity and p53-mediated cell cycle arrest and 
apoptosis (Roe et al., 2006). Thus, one 
must consider the possibility that UCP-
mediated degradation of pVHL will influ-
ence the biological activities associated 
with one or more of these other pVHL 
binding proteins, which consequently aid 
in the process of tumorigenesis. Also, as 
noted by Jung et al., UCP may catalyze 
E3-dependent or -independent ubiquitin-
mediated degradation of additional sub-
strates, besides pVHL, whose loss will 
ultimately promote cancer development. 
These outstanding questions notwith-
standing, the discovery of E2-EPF UCP 
is primed to ignite the next chapter of the 
molecular mechanisms in pVHL-mediated 
neoplasia.
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